The effectiveness of Tiotropium Add-on therapy using a Real-world cohort of patients with Asthma (Tiotropium therapy in Asthma)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/30994
• EU PAS number:
  EUPAS29889
• Study ID:
  30994
• Official title and acronym:
  The effectiveness of Tiotropium Add-on therapy using a Real-world cohort of patients with Asthma (Tiotropium therapy in Asthma)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy
• Study status:
  Ongoing

Research institutions and networks

Institutions

eMAX Health

Study timelines

Date when funding contract was signed

Planned: 07/06/2018

Actual: 08/06/2018

Study start date

Planned: 05/02/2019

Actual: 15/03/2019

Data analysis start date

Planned: 05/02/2019

Date of final study report

Planned: 31/08/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer-ingelheim Pharmaceuticals

Study protocol

Initial protocol

BI Tio-Asthma protocol 03-13-2019_2

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable